Schering-Plough, Roche settle PEG suits

SGP and Roche (SWX: ROCZ) cross-licensed their peginterferon technologies, ending their patent disputes over SGP's Peg-Intron and ROCZ's Pegasys, similar products for hepatitis C virus (HCV). Legal action was begun by ENZN, first against Shearwater Polymers, which provided PEG technology to ROCZ, and then against ROCZ, following ROCZ's Pegasys NDA submission. ROCZ then sued SGP, which uses ENZN's pegylation technology, claiming SGP had infringed some of its PEG technology. ...